Background Although pre-clinical experiments associate cannabinoids with reduced
depressive symptoms, there is a paucity of clinical evidence. This study aims to analyze the …

Depression is characterized by continuous low mood and loss of interest or pleasure in
enjoyable activities. First-line medications for mood disorders mostly target the …

Background: Anxiety and depressive disorders are highly prevalent. Patients are
increasingly using medicinal cannabis products to treat these disorders, but little is known …

Background Clinical evidence on the use of cannabidiol (CBD) for sleep remains limited.
Even fewer studies have tested the comparative effectiveness of cannabinoid formulations …

The therapeutic potential of medical cannabis to treat a variety of conditions is becoming
increasingly recognised. Globally, a large number of countries have now legalised cannabis …

Objective Expanding access to legal cannabis has dovetailed with increased interest in
medical cannabis (MC) use; however, there is a paucity of research examining MC use to …

Background Evidence for long-term effectiveness of commercial cannabis products used to
treat medical symptoms is inconsistent, despite increasingly widespread use. Objective To …

Purpose: Opioid use rates have dropped as North American patients gain access to medical
cannabis, indicating a harm reduction role, yet health outcomes remain mostly unexplored …

Introduction: We measure for the first time the associations between subjective patient
experiences of feeling “high” and treatment outcomes during real-time Cannabis flower …

Aim: To characterize perceived benefits and challenges experienced by medicinal cannabis
users. Methods: An anonymous online survey collected demographics, health information …